QAS523
Total Payments
$1.3M
Transactions
7
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $48,165 | 3 | 1 |
| 2017 | $1.2M | 4 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FIRST IN HUMAN SINGLE AND MULTIPLE DOSE ESCALATION STUDY OF QAS523 FOR SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY ADULT AND OLDER VOLUNTEERS | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| FIRST IN HUMAN SINGLE AND MULTIPLE DOSE ESCALATION STUDY OF QAS523 FOR SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY ADULT AND OLDER VOLUNTEERS | NOVARTIS PHARMACEUTICALS CORPORATION | $22,458 | 1 |
Top Doctors Receiving Payments for QAS523
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $1.2M | 5 |
| , MD | Specialist | Cape Coral, FL | $22,458 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 1
- Transactions 7
About QAS523
QAS523 is a drug associated with $1.3M in payments to 1 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $48,165 was paid across 3 transactions to 1 doctors.
The most common payment nature for QAS523 is "Unspecified" ($1.3M, 100.0% of total).
QAS523 is associated with 2 research studies, including "FIRST IN HUMAN SINGLE AND MULTIPLE DOSE ESCALATION STUDY OF QAS523 FOR SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY ADULT AND OLDER VOLUNTEERS" ($1.2M).